Sinomenine prevents metastasis of human osteosarcoma cells via S phase arrest and suppression of tumor-related neovascularization and osteolysis through the CXCR4-STAT3 pathway

International Journal of Oncology

Volumn 48, Issue 5, 2016, Pages 2098-2112

  Xie, Tao ^a   Ren, Hai Yong ^a   Lin, Hai Qing ^b   Mao, Jin Ping ^a   Zhu, Ting ^a   Wang, Sheng Dong ^a   Ye, Zhao Ming ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Second Jiaxing Hospital   (China)

Author keywords

CXCR4; Invasion; Metastasis; Neovascularization; Osteoclastogenesis; Osteosarcoma; Sinomenine

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GELATINASE A; GELATINASE B; OSTEOCLAST DIFFERENTIATION FACTOR; SINOMENINE; STAT3 PROTEIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ARHGEF3 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; MORPHINAN DERIVATIVE; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR;

ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; METASTASIS; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT; TUMOR INVASION; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BONE NEOPLASMS; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MORPHINANS; NEOPLASM METASTASIS; OSTEOSARCOMA; RECEPTORS, CXCR4; RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS; S PHASE CELL CYCLE CHECKPOINTS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962503029     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3416     Document Type: Article

References (41)

1. Quaye AA, Raskin KA, Ecker JL and Leffert LR: Management of a parturient with high-grade osteosarcoma of the proximal femur: A multidisciplinary approach. Int J Obstet Anesth 19: 340-342, 2010.
2. Raymond AK and Jaffe N: Osteosarcoma multidisciplinary approach to the management from the pathologist's perspective. Cancer Treat Res 152: 63-84, 2009.
3. Weiss A, Gill J, Goldberg J, Lagmay J, Spraker-Perlman H, Venkatramani R and Reed D: Advances in therapy for pediatric sarcomas. Curr Oncol Rep 16: 395, 2014.
4. Kudawara I, Aoki Y, Ueda T, Araki N, Naka N, Nakanishi H, Matsumine A, Ieguchi M, Mori S, Myoui A, et al: Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: A phase II trial in Japan. J Chemother 25: 41-48, 2013.
5. Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, et al; Cooperative German-Austrian-Swiss Osteosarcoma Study Group: Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21: 2011-2018, 2003.
6. Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G, Kabisch H, et al: Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23: 559-568, 2005.
7. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A and Engler JA: Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 4: 197-250, 1993.
8. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J and Kikuchi M: Emmprin (basigin/CD147): Matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 56: 359-367, 2006.
9. Clézardin P: The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: Physiopathology and clinical implications. Bull Cancer 98: 837-846, 2011 (In French).
10. Yamasaki H: Pharmacology of sinomenine, an anti-rheumatic alkaloid from Sinomenium acutum. Acta Med Okayama 30: 1-20, 1976.
11. Zhou L, Luan H, Liu Q, Jiang T, Liang H, Dong X and Shang H: Activation of PI3K/Akt and ERK signaling pathways antagonized sinomenine-induced lung cancer cell apoptosis. Mol Med Rep 5: 1256-1260, 2012.
12. Li XJ, Yue PY, Ha WY, Wong DY, Tin MM, Wang PX, Wong RN and Liu L: Effect of sinomenine on gene expression of the IL-1 beta-activated human synovial sarcoma. Life Sci 79: 665-673, 2006.
13. Lu XL, Zeng J, Chen YL, He PM, Wen MX, Ren MD, Hu YN, Lu GF and He S: Sinomenine hydrochloride inhibits human hepatocellular carcinoma cell growth in vitro and in vivo: Involvement of cell cycle arrest and apoptosis induction. Int J Oncol 42: 229-238, 2013.
14. Lv Y, Li C, Li S and Hao Z: Sinomenine inhibits proliferation of SGC-7901 gastric adenocarcinoma cells via suppression of cyclooxygenase-2 expression. Oncol Lett 2: 741-745, 2011.
15. Li X, Wang K, Ren Y, Zhang L, Tang XJ, Zhang HM, Zhao CQ, Liu PJ, Zhang JM and He JJ: MAPK signaling mediates sinomenine hydrochloride-induced human breast cancer cell death via both reactive oxygen species-dependent and-independent pathways: An in vitro and in vivo study. Cell Death Dis 5: e1356, 2014.
16. Ou YQ, Chen LH, Li XJ, Lin ZB and Li WD: Sinomenine influences capacity for invasion and migration in activated human monocytic THP-1 cells by inhibiting the expression of MMP-2, MMP-9, and CD147. Acta Pharmacol Sin 30: 435-441, 2009.
17. Song L, Liu D, Zhao Y, He J, Kang H, Dai Z, Wang X, Zhang S and Zan Y: Sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-κB activation mediated by IL-4/miR-324-5p/CUEDC2 axis. Biochem Biophys Res Commun 464: 705-710, 2015.
18. Zhou Q, Zhu Y, Deng Z, Long H, Zhang S and Chen X: VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol 20: 13-19, 2011.
19. Benayoun Y, Petellat F, Leclerc O, et al: Current treatments for corneal neovascularization. J Fr Ophtalmol 38: 996-1008, 2015.
20. Yan L, Zucker S and Toole BP: Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 93: 199-204, 2005.
21. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, et al: Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23: 2004-2011, 2005.
22. Chen DP, Wong CK, Leung PC, Fung KP, Lau CB, Lau CP, Li EK, Tam LS and Lam CW: Anti-inflammatory activities of Chinese herbal medicine sinomenine and Liang Miao San on tumor necrosis factor-α-activated human fibroblast-like synoviocytes in rheumatoid arthritis. J Ethnopharmacol 137: 457-468, 2011.
23. Qian L, Xu Z, Zhang W, Wilson B, Hong JS and Flood PM: Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J Neuroinflammation 4: 23, 2007.
24. Tang Q, Luo J, Zhu Q, Li Y and Yin S: Synthesis and antiinflammatory activities investigation of sinomenine derivatives on ring C. Nat Prod Res 20: 1015-1023, 2006.
25. Liu Z, Duan ZJ, Chang JY, Zhang ZF, Chu R, Li YL, Dai KH, Mo GQ and Chang QY: Sinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expression. PLoS One 9: e98560, 2014.
26. Liao F, Yang Z, Lu X, Guo X and Dong W: Sinomenine sensitizes gastric cancer cells to 5-fluorouracil in vitro and in vivo. Oncol Lett 6: 1604-1610, 2013.
27. Chen Y, Zhang L, Lu X, Wu K, Zeng J, Gao Y, Shi Q, Wang X, Chang LS and He D: Sinomenine reverses multidrug resistance in bladder cancer cells via P-glycoprotein-dependent and independent manners. Pharmazie 69: 48-54, 2014.
28. Zhang JX, Yang ZR, Wu DD, Song J, Guo XF, Wang J and Dong WG: Suppressive effect of sinomenine combined with 5-fluorouracil on colon carcinoma cell growth. Asian Pac J Cancer Prev 15: 6737-6743, 2014.
29. Zhang H, Ren Y, Tang X, Wang K, Liu Y, Zhang L, Li X, Liu P, Zhao C and He J: Vascular normalization induced by sinomenine hydrochloride results in suppressed mammary tumor growth and metastasis. Sci Rep 5: 8888, 2015.
30. Li X, He L, Hu Y, Duan H, Li X, Tan S, Zou M, Gu C, Zeng X, Yu L, et al: Sinomenine suppresses osteoclast formation and Mycobacterium tuberculosis H37Ra-induced bone loss by modulating RANKL signaling pathways. PLoS One 8: e74274, 2013.
31. Ruffini PA, Morandi P, Cabioglu N, Altundag K and Cristofanilli M: Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 109: 2392-2404, 2007.
32. Micucci C, Matacchione G, Valli D, Orciari S and Catalano A: HIF2α is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma. Br J Cancer 113: 1178-1185, 2015.
33. Gu JY, Shi HF, Gao XL, Ma QQ and Zhang B: Effect of CXCR4 pretreated with ultrasound-exposed microbubbles on accelerating homing of bone marrow mesenchymal stem cells to ischemic myocardium in AMI rats. Asian Pac J Trop Med 8: 766-771, 2015.
34. Sand LG, Scotlandi K, Berghuis D, Snaar-Jagalska BE, Picci P, Schmidt T, Szuhai K and Hogendoorn PC: CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients. Eur J Cancer 51: 2624-2633, 2015.
35. Han AR, Lee JY, Kim HJ, Min WS, Park G and Kim SH: A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment. Oncol Rep 34: 2880-2888, 2015.
36. Liu X, Xiao Q, Bai X, Yu Z, Sun M, Zhao H, Mi X, Wang E, Yao W, Jin F, et al: Activation of STAT3 is involved in malignancy mediated by CXCL12-CXCR4 signaling in human breast cancer. Oncol Rep 32: 2760-2768, 2014.
37. Shen HB, Gu ZQ, Jian K and Qi J: CXCR4-mediated Stat3 activation is essential for CXCL12-induced cell invasion in bladder cancer. Tumour Biol 34: 1839-1845, 2013.
38. Hanada R, Hanada T, Sigl V, Schramek D and Penninger JM: RANKL/RANK-beyond bones. J Mol Med (Berl) 89: 647-656, 2011.
39. Li C, Shi X, Zhou G, Liu X, Wu S and Zhao J: The canonical Wnt-beta-catenin pathway in development and chemotherapy of osteosarcoma. Front Biosci (Landmark Ed) 18: 1384-1391, 2013.
40. Moore AS, Dernell WS, Ogilvie GK, Kristal O, Elmslie R, Kitchell B, Susaneck S, Rosenthal R, Klein MK, Obradovich J, et al: Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: A randomized, double-blind, placebocontrolled study. J Vet Intern Med 21: 783-790, 2007.
41. Durnali A, Alkis N, Cangur S, Yukruk FA, Inal A, Tokluoglu S, Seker MM, Bal O, Akman T, Inanc M, et al: Prognostic factors for teenage and adult patients with high-grade osteosarcoma: An analysis of 240 patients. Med Oncol 30: 624, 2013.